TokenPost·
Immix Biopharma Reports $340.9 Million in Cash, Cash Equivalents and Marketable Securities
The company expects the balance at quarter-end to fund operations into mid-2028. Third-quarter operating expenses were $15.9 million.
More news
- TokenPostIntuitive Machines Narrows 2026 Revenue Outlook to $920 Million-$950 Million
- TokenPostDemocrats Open Inquiry Into Nvidia’s China Chip Export Deal
- TokenPostPump.fun Adds Trading Access to Sei Tokens Through Cross-Chain Service
- TokenPostAfya Posts R$985.16 Million in Revenue and R$1.88 GAAP EPS
- TokenPostAya Raises Zgounder 2026 Production Guidance to 5.6M–5.8M Ounces
- TokenPostMattr Posts C$423.4 Million in Q3 Revenue, C$0.43 Non-GAAP EPS